Humacyte
HUMA
88 hedge funds and large institutions have $51.1M invested in Humacyte in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 17 reducing their positions, and 6 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 17
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
6% more funds holding
Funds holding: 83 → 88 (+5)
1.29% more ownership
Funds ownership: 16.06% → 17.35% (+1.3%)
5% more capital invested
Capital invested by funds: $48.7M → $51.1M (+$2.42M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
78% less call options, than puts
Call options by funds: $104K | Put options by funds: $480K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.02M |
| 2 |
Morgan Stanley
New York
|
+$588K |
| 3 |
Two Sigma Investments
New York
|
+$552K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$268K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
-$587K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$240K |
| 3 |
Bank of New York Mellon
New York
|
-$226K |
| 4 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
-$123K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$115K |
HUMA Hedge Fund Activity: Q4 2023 in Review
88 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q4 2023, worth a combined $51.1M — up 5% from $48.7M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new HUMA positions and 6 closed out — a net gain of 5 holders — while 35 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $1.02M. The largest seller was Rokos Capital Management (UK), exiting entirely with an estimated $587K sold.
- 88 institutional investors held Humacyte (HUMA) as of Q4 2023, up from 83 in Q3 2023.
- Funds reported $51.1M of Humacyte stock for Q4 2023, up 5% quarter-over-quarter.
- 11 funds opened new Humacyte positions in Q4 2023 and 6 closed out, a net change of +5 holders.
- The largest Humacyte buyer in Q4 2023 was BlackRock, an estimated $1.02M added.
- The largest Humacyte seller in Q4 2023 was Rokos Capital Management (UK), an estimated $587K sold.
Based on aggregated 13F filings for Q4 2023.